- Home
- TTGT vs CGEM Comparison
TTGT vs CGEM Comparison
Compare TTGT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- CGEM
- Stock Information
- Founded
- TTGT 1999
- CGEM 2016
- Country
- TTGT United States
- CGEM United States
- Employees
- TTGT N/A
- CGEM N/A
- Industry
- TTGT Telecommunications Equipment
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- CGEM Health Care
- Exchange
- TTGT Nasdaq
- CGEM Nasdaq
- Market Cap
- TTGT 598.8M
- CGEM 530.0M
- IPO Year
- TTGT 2007
- CGEM 2021
- Fundamental
- Price
- TTGT $6.82
- CGEM $7.67
- Analyst Decision
- TTGT Buy
- CGEM Strong Buy
- Analyst Count
- TTGT 6
- CGEM 5
- Target Price
- TTGT $19.33
- CGEM $30.00
- AVG Volume (30 Days)
- TTGT 496.5K
- CGEM 324.5K
- Earning Date
- TTGT 08-07-2025
- CGEM 08-07-2025
- Dividend Yield
- TTGT N/A
- CGEM N/A
- EPS Growth
- TTGT N/A
- CGEM N/A
- EPS
- TTGT N/A
- CGEM N/A
- Revenue
- TTGT $284,897,000.00
- CGEM N/A
- Revenue This Year
- TTGT $79.55
- CGEM N/A
- Revenue Next Year
- TTGT N/A
- CGEM N/A
- P/E Ratio
- TTGT N/A
- CGEM N/A
- Revenue Growth
- TTGT 13.01
- CGEM N/A
- 52 Week Low
- TTGT $6.51
- CGEM $6.85
- 52 Week High
- TTGT $33.08
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- TTGT 40.38
- CGEM 38.41
- Support Level
- TTGT $6.51
- CGEM $8.47
- Resistance Level
- TTGT $7.26
- CGEM $9.25
- Average True Range (ATR)
- TTGT 0.70
- CGEM 0.45
- MACD
- TTGT -0.02
- CGEM -0.12
- Stochastic Oscillator
- TTGT 13.54
- CGEM 5.06
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.